CSS
CRDF icon

Cubist Systematic Strategies’s Cardiff Oncology CRDF Stock Holding History

Cubist Systematic Strategies’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$183K Buy
+88,903
New +$246K ﹤0.01% 2676
2024
Q3 		– Sell
-68,730
Closed -$153K – 3054
2024
Q2 		$153K Buy
68,730
+36,441
+113% +$137K ﹤0.01% 2563
2024
Q1 		$172K Buy
+32,289
New +$85.8K ﹤0.01% 3140
2022
Q2 		– Sell
-69,090
Closed -$171K – 4384
2022
Q1 		$171K Buy
69,090
+59,639
+631% +$211K ﹤0.01% 3093
2021
Q4 		$57K Sell
9,451
-16,233
-63% -$96.8K ﹤0.01% 3292
2021
Q3 		$171K Sell
25,684
-21,660
-46% -$136K ﹤0.01% 2629
2021
Q2 		$315K Sell
47,344
-44,679
-49% -$379K ﹤0.01% 2294
2021
Q1 		$852K Buy
92,023
+25,334
+38% +$308K 0.01% 1636
2020
Q4 		$1.2M Buy
+66,689
New +$1.17M 0.02% 1260

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cubist Systematic Strategies's CRDF Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Cardiff Oncology (CRDF) in Q3 2025: 88,903 shares worth $183K. The stake represents ﹤0.01% of the portfolio and ranks #2676 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in CRDF as recently as Q2 2024.

Cubist Systematic Strategies first reported a position in CRDF in Q4 2020 and has held it in 9 quarters since. The position peaked at $1.2M in Q4 2020. 112 funds tracked by Wall St. Rank hold CRDF as of Q3 2025.

  • Cubist Systematic Strategies held 88,903 shares of Cardiff Oncology worth $183K as of Q3 2025.
  • Cardiff Oncology was a new Cubist Systematic Strategies position in Q3 2025.
  • Cardiff Oncology made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2676 holding.
  • Cubist Systematic Strategies first reported a position in Cardiff Oncology in Q4 2020 and has held it in 9 quarters since.
  • Cubist Systematic Strategies's Cardiff Oncology position peaked at $1.2M in Q4 2020.
  • 112 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.